There are currently 83 active clinical trials seeking participants for Lymphoma research studies. The states with the highest number of trials for Lymphoma participants are Ohio, Illinois, California and New York.
Epcoritamab in Patients with Follicular Lymphoma Not Accomplishing a CR with Upfront Chemoimmunotherapy
NCT06510361
Recruiting
This research is being done to see if epcoritamab is effective in treating follicular lymphoma as a second line of treatment. The name of the study drug in this research study is: -Epcoritamab (a type of antibody)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Lymphoma, Follicular Lymphoma, Lymphoma,Non-Hodgkin, Lymphoma, Non-Hodgkin's, Adult
Register for Updates
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
NCT06326463
Recruiting
The study participant has one of the following blood cancers: acute myelogenous leukemia (AML)/myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (B-ALL, T-ALL) or Lymphoma. Your cancer has been difficult to treat (refractory) or has come back after treatment (relapse). Primary Objective To determine the safety and maximum tolerated dose of intravenous infusions of escalating doses of CD70-CAR T cells in patients (≤21 years) with recurrent/refractory CD70+ hematological malignancies... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
12/16/2024
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Hematologic Malignancy, ALL, Childhood, AML, Childhood, Lymphoma, MDS
Register for Updates
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
NCT05464719
Recruiting
To learn if loncastuximab tesirine (called "lonca" in this informed consent form) can help to control large B-cell lymphoma that is relapsed or refractory after receiving CAR T-cell therapy. The safety and possible effects of the study therapy will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Large B-cell Lymphoma, Lymphoma
Register for Updates
Living Well With Lymphoma
NCT06047626
Recruiting
In this study the investigators are proposing to evaluate the efficacy, sustainability, and mechanisms of 3 months of individualized counseling of the FRD delivered by registered dietitians, over 8 sessions by phone/video conferencing on fatigue, quality of life, and associated symptoms in persistently fatigued lymphoma cancer survivors compared to 3 months of individualized counseling of the attention control (matched for time and frequency of interactions with the FRD) the General Health Curri... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/12/2024
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Lymphoma
Register for Updates
High- Fiber/ Low-fat Diet for Prevention of Recurrent Clostridioides Difficile Infection in Oncology
NCT04940468
Recruiting
The primary objective of the study is to determine whether dietary intervention to increase fiber and decrease fat reduces C. difficile infection recurrence in a cohort of oncology patients.
Gender:
ALL
Ages:
9 years and above
Trial Updated:
12/03/2024
Locations: Childrens Hospital Colorado, Aurora, Colorado +1 locations
Conditions: Leukemia, Lymphocytic, Acute, Leukemia, Myeloid, Acute, Lymphoma, Clostridium Difficile Infection
Register for Updates
Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
NCT05011045
Recruiting
This study assesses neurocognitive outcomes after receiving radiation therapy to the brain (whole brain radiation therapy) in patients with blood cancers (hematologic malignancies). This may help researchers learn more about the effects of whole brain radiation therapy on memory and thinking in patients with blood cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/19/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Central Nervous System Lymphoma, Hematopoietic and Lymphoid Cell Neoplasm, Leukemia, Lymphoma, Plasma Cell Myeloma, Secondary Central Nervous System Lymphoma
Register for Updates
Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL
NCT06475235
Recruiting
This research study is studying if the investigational drug, Pembrolizumab, in combination with chemotherapy helps primary central nervous system lymphoma with acceptable side effects. This research study involves a combination of the below drugs: * Pembrolizumab (a type of monoclonal antibody) * Methotrexate (a type of anti-metabolite) * Temozolomide (a type of alkylating agent) * Rituximab (a type of antibody)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts +1 locations
Conditions: Lymphoma, Primary Central Nervous System Lymphoma
Register for Updates
Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy
NCT06049134
Recruiting
To compare the effects of a pneumococcal vaccine called PCV20 when given as a single dose versus a boosted regimen to patients who previously received anti-CD20 therapy as treatment for B cell lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Lymphoma
Register for Updates
Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas
NCT05676450
Recruiting
To test the feasibility of collecting cell-free DNA (cfDNA) samples from DLBCL patients before and after treatment. cfDNA is DNA traveling in your blood outside of a cell and is easily collected from blood samples drawn using the vein puncture method.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/12/2024
Locations: MD Anderson Cancer Center, Houston, Texas +1 locations
Conditions: Lymphoma
Register for Updates
Dietary and Topical Magnesium Replacement or Supplementation in Patients with Lymphoma
NCT05294367
Recruiting
This early phase I trial investigates the effect of dietary and topical magnesium replacement on magnesium blood levels in patients with lymphoma. Magnesium is an element in the body that is important to cell health. The body cannot make magnesium and it typically comes from the food we eat. In patients who are ill, magnesium is often replaced intravenously (IV) through a vein or by mouth. This study may help researchers find out if being on a magnesium rich diet and using a magnesium lotion on... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/06/2024
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Lymphoma
Register for Updates
Post-Op Pain Control for Prophylactic Intramedullary Nailing.
NCT03823534
Recruiting
Nationally, the opioid crisis has become a major epidemic with increasing mortality rates each year. Orthopedic surgeons routinely prescribe narcotics instead of NSAIDs for post-op pain control because of risk of delayed healing and nonunion due to NSAID use. Orthopedic oncology, however, has a unique subset of patients that undergo prophylactic placement of intramedullary femoral nails. Because no fracture is present, these patients do not rely on inflammatory healing factors, allowing for post... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/04/2024
Locations: Saint Louis University, Saint Louis, Missouri
Conditions: Bone Metastases, Lymphoma, Multiple Myeloma, Opioid Use, Pain
Register for Updates
Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL
NCT02690545
Recruiting
The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancer. This research study combines two different ways of fighting disease: antibodies and T cells. Antibodies are proteins that protect the body from disease caused by bacteria or toxic substances. Antibodies work by binding those bacteria or substances, which stops them from growing and causing bad effects. T cells, also called T lymphocytes, are special infection-fighting blood cells that... Read More
Gender:
ALL
Ages:
3 years and above
Trial Updated:
10/28/2024
Locations: Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina
Conditions: Lymphoma, Lymphoma, Non-Hodgkin, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type
Register for Updates